Point72 Asset Management
ESPR icon

Point72 Asset Management’s Esperion Therapeutics ESPR Stock Holding History

Point72 Asset Management’s Portfolio ESPR Stock Details ESPR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-260,000
Closed -$577K – 2088
2024
Q2 		$577K Buy
260,000
+60,000
+30% +$141K ﹤0.01% 1405
2024
Q1 		$536K Buy
+200,000
New +$486K ﹤0.01% 1629
2023
Q1 		– Sell
-150,000
Closed -$935K – 2319
2022
Q4 		$935K Buy
150,000
+100,000
+200% +$715K ﹤0.01% 1061
2022
Q3 		$335K Buy
+50,000
New +$343K ﹤0.01% 1218

Other funds holding ESPR

Glazer Capital LLC
Glazer Capital LLC New York $4.07B AUM 78.71% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
TC
Trium Capital London, United Kingdom $163M AUM 45.8% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
AQR Arbitrage
AQR Arbitrage Greenwich, Connecticut $7.02B AUM 31.58% 1-Year Est. Return
OBAM
ODDO BHF Asset Management Paris, France $2.16B AUM 43.32% 1-Year Est. Return

Point72 Asset Management's ESPR Position: Q2 2026 in Review

Point72 Asset Management sold out of Esperion Therapeutics (ESPR) in Q2 2026, closing a stake of 1,689,372 shares — an estimated $4.63M sold.

Point72 Asset Management first reported a position in ESPR in Q4 2014 and held it in 21 quarters. The position peaked at $22.5M in Q3 2018. 192 funds tracked by Wall St. Rank hold ESPR as of Q2 2026.

  • Point72 Asset Management reported no remaining Esperion Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Point72 Asset Management sold 1,689,372 Esperion Therapeutics shares in Q2 2026, an estimated $4.63M.
  • Point72 Asset Management first reported a position in Esperion Therapeutics in Q4 2014 and held it in 21 quarters.
  • Point72 Asset Management's Esperion Therapeutics position peaked at $22.5M in Q3 2018.
  • 192 funds tracked by Wall St. Rank held Esperion Therapeutics as of Q2 2026.

Based on Point72 Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.